Clinical Trials on Beta-Galactosidase-1 (GLB1) Deficiency

Total 361 results

University of Washington
Bill and Melinda Gates Foundation

Completed

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP)

HIV Infections | HIV-1 Infections

Kenya, Uganda
Oslo University Hospital
Karolinska University Hospital; Tine

Completed

The Effect of Probiotics in HIV-1 Infection (ProGut)

HIV-1 Infection

Norway, Sweden
Mount Sinai Hospital, Canada
CIHR Canadian HIV Trials Network

Unknown

Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals (ProSPAR)

HIV-1 Infection

Canada
United BioPharma

Not yet recruiting

UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

HIV-1 Infection
United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
Prema Menezes, PhD, PA-C
Gilead Sciences

Completed

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

HIV-1 Infection

United States
Bio Products Laboratory

Completed

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

Common Variable Immunodeficiency | Wiskott-Aldrich Syndrome | X-linked Agammaglobulinemia | Primary Immune Deficiency Disorders | Hyper-IgM Syndrome

United States, Chile, Israel
Stanford University

Withdrawn

Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses (A1AT for NMO)

Neuromyelitis Optica

United States
McMaster University
St. Joseph's Healthcare Hamilton

Recruiting

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

Bronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Emphysema | Pulmonary Fibrosis | Alpha 1-Antitrypsin Deficiency | Bronchopulmonary Dysplasia | Sarcoidosis, Pulmonary

Canada
University of Roma La Sapienza

Unknown

Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection (PRIMO)

HIV-1-infection

Italy
Gilead Sciences

Completed

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

HIV Infections | Acquired Immunodeficiency Syndrome | HIV-1

United States, Canada
Icahn School of Medicine at Mount Sinai
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Targeting Platelets in Chronic HIV Infection

HIV-1 Infection

United States
Medical University of Warsaw

Not yet recruiting

HIV Drug Resistance Pattern Due to Migration in Poland

HIV Infections | HIV-1-infection | Resistant Infection

Poland
ADRIANO LAZZARIN, MD
Ministero della Salute, Italy

Unknown

Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI). (P25-INACTION)

HIV-1-infection

Italy
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM (RALAM-RollOver)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
David Garcia Cinca
Fundacion Clinic per a la Recerca Biomédica

Unknown

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen (RALAM-II)

HIV Infections | HIV Seropositivity | HIV-1-infection

Spain
Chiltern Pesquisa Clinica Ltda

Completed

Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

H1N1 Influenza Virus | Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Brazil
University Hospital, Ghent
KU Leuven; Universitair Ziekenhuis Brussel; Vrije Universiteit Brussel; Centre... and other collaborators

Not yet recruiting

Immuno-virological Evaluation of Persons Living With HIV (PLWH)

HIV Seropositivity | HIV-1-infection

Belgium
Calmy Alexandra

Completed

Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV) (Simpl'HIV)

Antiretroviral Therapy | HIV-1-infection | Maintenance Therapy

Switzerland
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
Shanghai Public Health Clinical Center

Completed

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

HIV-1-infection

China
AbbVie

Terminated

A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation (COPI)

HIV-1 Infection

Russian Federation
Luis Montaner
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Unknown

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

HIV/AIDS | HIV | HIV-1 Infection

United States
AIDS Healthcare Foundation
HIV Immunotherapeutics Institute

Completed

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

HIV-1-infection | Gut Inflammation

United States
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

HIV-1 Infection

France
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico
University of Alabama at Birmingham
National Institute of Mental Health (NIMH); Washington University School of... and other collaborators

Completed

Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ (SKILLZ)

HIV Infections | Pregnancy Related | Mental Health Wellness 1 | STI

Zambia
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

HIV-1

United States
CSL Behring

Completed

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Cystic Fibrosis

Bulgaria, Hungary, Poland, United Kingdom
Chelsea Therapeutics

Terminated

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

Parkinson's Disease | Pure Autonomic Failure | Dopamine Beta Hydroxylase Deficiency | Symptomatic Neurogenic Orthostatic Hypotension | Multiple Systems Atrophy

United States
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

HIV Infection | HIV-1 | Human Immunodeficiency Virus (HIV)

United States, Australia, Canada, Puerto Rico
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) (WIP)

HIV-1 Infection
PENTA Foundation
Medical Research Council; ANRS, Emerging Infectious Diseases

Completed

KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) (KONCERT)

Antiretroviral Therapy in HIV-1 Infected Children

Netherlands, Germany, United Kingdom, Ireland, Thailand
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Janssen R&D Ireland

Completed

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

United States, Canada, Germany, Israel, Italy, South Africa, Spain, United Kingdom, Brazil, France, Netherlands
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome | Lipoprotein Lipase Deficiency | Hyperlipoproteinemia Type 1

Canada
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Compassionate Use

Human Immunodeficiency Virus Type 1
Janssen-Cilag S.p.A.

Completed

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients (MONARCH)

Human Immunodeficiency Virus 1
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN) (ODIN)

Human Immunodeficiency Virus - Type 1

United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Centre for the...

Recruiting

Simplifying Treatment and Monitoring for HIV (STREAM HIV)

HIV/AIDS | HIV-1-infection

South Africa
University Hospital, Montpellier
Institute of Human Genetics, France

Completed

Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy (RALNOVO)

HIV-1 Infection

France
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (SALIF)

Human Immunodeficiency Virus-type 1 Infection

South Africa, Kenya, Thailand, Uganda, Cameroon, Senegal
Janssen Pharmaceutica

Withdrawn

A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients

Human Immunodeficiency Virus-Type 1
Tibotec Pharmaceuticals, Ireland

Completed

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

Human Immunodeficiency Virus Type 1

United States, France, United Kingdom, China, Germany, South Africa, Russian Federation, Argentina, Brazil, Puerto Rico, Austria, Thailand, Mexico, Uganda
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Human Immunodeficiency Virus Type 1

Germany
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
Hospitales Universitarios Virgen del Rocío

Completed

Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (RAET)

HIV Infections | HIV-1 Infection

Spain

3

Subscribe